Aligos Therapeutics price to sales ratio ALGS

Market value divided by revenue over the last twelve months, since 2024.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 3.2×; Jul 2026
3-year median: 10.0×
3-year range: 3.1× to 42.4×

Aligos Therapeutics' price to sales ratio is not a meaningful number today: no cover page share count was public by this date.

It was last meaningful in Jul 2026, at 3.2×.

On the days it had one over the last 3 years, its median was 10.0×, from 3.1× in Jul 2026 to 42.4× in Jan 2025.

Price to sales ratio over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	3.2×	3.1×	13.1×
2025	13.8×	4.1×	42.4×
2024	40.2×	4.1×	40.2×

What the price to sales ratio tells you

Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.

Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.

More on Aligos Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.